Form 4: AXIM Biotechnologies CEO Acquires Convertible Note

John W. Huemoeller II, CEO of AXIM Biotechnologies, acquired a convertible note worth $250,000, convertible into common stock at $0.02 per share.

Summary

• On March 15, 2024, John W. Huemoeller II, the CEO of AXIM Biotechnologies, acquired a convertible note with a face value of $250,000.
• The note is convertible into shares of AXIM Biotechnologies' common stock at a conversion price of $0.02 per share.
• Following this transaction, Huemoeller directly owns 42,500,000 shares of common stock.
• The convertible note is exercisable from March 15, 2024, and expires on March 1, 2034.
• The note can be converted into 12,500,000 shares of common stock.

Sentiment

Score: 5

Explanation: The sentiment is neutral as it simply reports a transaction by the CEO. The acquisition of a convertible note could be seen as a positive sign of confidence, but without further context, it's difficult to assess the overall impact.

Industry Context

Form 4 filings are standard practice and provide transparency into the transactions of company insiders, allowing investors to track management's alignment with shareholder interests.

Stakeholder Impact

• Shareholders may view the CEO's acquisition of a convertible note as a sign of confidence in the company's future prospects.

Key Dates

Keywords

Convertible Note, Form 4, Beneficial Ownership, AXIM Biotechnologies, Huemoeller, CEO, Securities